PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA Drug-Free Alzheimer's Approach Falls Short of Its Main Target
A home-use device that flashes light and plays sound at 40 pulses per second did not slow Alzheimer's disease overall in its largest test so far, researchers reported this week in Boston. People with milder disease who used it did decline more slowly on several measures, but those results are early and not yet confirmed.
The pivotal HOPE trial tested Spectris, a headset made by Cambridge, Massachusetts-based Cognito Therapeutics. Results were presented at the Clinical Trials on Alzheimer's Disease conference, held Nov. 16 to 19, by senior author Marwan Sabbagh of Barrow Neurological Institute.
The outcome matters to many families — the approach is non-invasive and drug-free, and it has drawn wide public interest. But a failed primary goal means the device has not shown it works for the full group it was designed to help.
Separating the Main Result From the Subgroup Signal
The 12-month trial enrolled 673 people with biomarker-confirmed Alzheimer's and Mini-Mental State Examination (MMSE) scores of 15 to 28. About half used the active device and the rest used a sham version. Participants were asked to use it about an hour a day. The study is registered as NCT05637801.
The primary goal was a combined score of memory testing and daily-living ability. In the main analysis of 663 participants, neither the primary nor the secondary goals differed significantly from sham.
The twist came in people with mild disease, defined as MMSE scores of 21 to 28. In that group of 395 participants, decline in daily activities slowed by 56% and decline on the Clinical Dementia Rating scale slowed by 47% compared with sham. These results are described as nominal and were not adjusted for testing multiple outcomes, which raises the chance that some findings occurred by luck.
The company also reported larger effects in 169 mild participants who used the device consistently for at least six months. Cognito acknowledged those analyses are subject to adherence bias and do not establish cause and effect, because people who stick with a treatment can differ from those who do not.
"The study did not meet its primary endpoint, but we remain intrigued by the mechanism," said Laura Nisenbaum, interim chief science officer at the Alzheimer's Drug Discovery Foundation, in comments to NeurologyLive.
The Science of 40-Hz Gamma Stimulation
Brain cells communicate through rhythmic electrical activity. One fast rhythm, called gamma, runs near 40 cycles per second and is linked to attention and memory. People with Alzheimer's tend to show weaker gamma activity.
The idea traces back to 2016, when MIT neuroscientists Li-Huei Tsai and Ed Boyden showed that light and sound pulsed at 40 Hz could trigger gamma waves in mice and appeared to clear amyloid plaques, the Boston Globe reported. Tsai and Boyden cofounded Cognito and remain scientific advisors, a financial tie readers should weigh. The trial itself was company-sponsored.
Cognito's chief executive, Christian Howell, told the Globe the device does not clear amyloid plaques or tau in people. That separates it from approved antibody drugs such as Leqembi and Kisunla, which target amyloid and carry a risk of temporary brain swelling.
Safety data showed device-related side effects in 18.3% of active users versus 15.5% on sham. Headache occurred in 5.7% versus 3.9%, tinnitus in 3.3% versus 1.2%, and seizures in 0.9% versus 0.3%. No unexpected device effects were reported, and the device is not expected to cause the brain swelling seen with anti-amyloid drugs.
Cautious Reactions and the Road to the FDA
This is not the first mixed result. Cognito's earlier phase 2 OVERTURE trial of 76 people also missed its primary clinical goal over six months, while showing nominally slower decline on daily-living and memory scores and on whole-brain volume, NeurologyLive reported. HOPE was designed to settle that question, and it did not deliver a clean answer.
Independent experts urged caution. "There's a hint that there may be something there, but it's unproven and needs to be verified," Heather Snyder, senior vice president of medical and scientific relations at the Alzheimer's Association, told the Globe. Stephanie Buss, a cognitive neurologist at Beth Israel Deaconess Medical Center who was not involved, said she wanted to learn more about the people who responded.
The evidence has clear limits. HOPE was a randomized, double-blind, sham-controlled trial, which is a strong design. But the positive findings come from a subgroup, the results have not been peer-reviewed, and the full data have not yet been published. The company said it will submit the results to the New England Journal of Medicine.
Spectris holds an FDA breakthrough device designation — which speeds review but is not approval. Cognito plans to meet with the FDA about a De Novo submission for early symptomatic Alzheimer's, and Howell told the Globe he hopes for authorization by the end of 2027. That timeline is the company's projection, not an agency decision. An open-label extension study continues.
The device is not authorized for sale as an Alzheimer's treatment. Families interested in the research should talk with a neurologist about approved options and clinical trials listed on ClinicalTrials.gov. Light and sound products sold online were not tested in this trial, and people with a seizure history should be especially careful with flashing light devices.
The next milestones are peer-reviewed publication and the FDA's response. Until then, the mild-disease signal remains a promising lead that needs a dedicated trial to confirm.
What Readers Want to Know
Did the flickering light therapy work? Not for the full trial group. It missed its primary goal, though people with mild Alzheimer's showed slower decline in early, unadjusted analyses.
What is 40-Hz gamma stimulation? It uses light and sound pulsed 40 times per second to encourage gamma brain rhythms, which tend to be weaker in Alzheimer's.
What side effects were reported? Headache, tinnitus, and, rarely, seizures were more common with the active device than with sham.
Can I buy the device now? No. Spectris is not authorized by the FDA as an Alzheimer's treatment.
When could the FDA decide? Cognito plans to approach the FDA, and its chief executive hopes for authorization by the end of 2027. The FDA has not made any decision.
Has the study been peer-reviewed? Not yet. The company says it will submit the results to a medical journal.
© 2026 NatureWorldNews.com All rights reserved. Do not reproduce without permission.


18 hours ago
7




















English (US) ·
French (CA) ·